Lantheus Strengthens its Alzheimer’s Disease Pipeline Through the Acquisition of Meilleur Technologies
Shots:
- Lantheus has agreed to acquire Meilleur Technologies, strengthening its Alzheimer’s disease pipeline
- As per the agreement, Lantheus will pay upfront, development & commercial milestones, and royalties based on research revenue & commercial sales
- The acquisition grants Lantheus with exclusive global rights of NAV-4694 (ß amyloid PET imaging agent), being investigated under P-III plus employed in academic & industry investigational therapeutic studies, complementing Lantheus' MK-6240 PET imaging agent, which targets tau tangles in Alzheimer’s disease
Ref: Lantheus | Image: Lantheus
Related Post:- Lantheus Acquires Cerveau Technologies to Expands Imaging Pipeline into Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
